Fante, who currently serves as Innocoll's chief commercial officer and head of business development, succeeds Anthony Zook, who retired from his role as Innocoll CEO.
Fante joined Innocoll in 2015 as chief commercial officer and head of business development.
In this role, he built an experienced, highly talented commercial team to prepare the company for commercialisation and also led all business development activities, including Innocoll's acquisition by Gurnet Point.
Prior to Innocoll, Fante spent nearly twenty years at AstraZeneca in the United States, serving in a variety of leadership roles, including president, US, CEO of North America and Regional vice president of the Americas.
He also formerly served as an independent director for Inhibikase Therapeutics, Inc. Fante graduated from Princeton University with a B.A. in Biology and received an MBA from the University of North Carolina at Chapel Hill.
Innocoll is a specialty pharmaceutical company focused on the development and commercialisation of pharmaceutical technologies Its current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management.
Gurnet Point Capital is a healthcare fund founded by Ernesto Bertarelli and led by Chris Viehbacher, who.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business